Nucleoside Analogs as Anti-HBV Agents

Author(s): Xiao-Xiong Zhou, Eddy Littler

Journal Name: Current Topics in Medicinal Chemistry

Volume 6 , Issue 9 , 2006

Become EABM
Become Reviewer


Chronic hepatitis B virus (HBV) infection affects about 400 million people worldwide. The development of nucleoside analogs that inhibit HBV polymerase provides an important approach for treating HBV infection. The approval of lamivudine, adefovir and entecavir represents a cornerstone of hepatitis B therapy. However, the challenges from the resistance and the off-therapy viral rebound are still unmet, and there is a need of developing new therapeutic agents. This review will discuss the structure-activity relationship of the most significant anti-HBV nucleoside analogs and the latest development in the field.

Keywords: Hepatitis B virus, hepatitis, nucleoside, nucleoside phosphonate, nucleotide, lamivudine, emtricitabine, entecavir, adefovir

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [851 - 865]
Pages: 15
DOI: 10.2174/156802606777303667
Price: $65

Article Metrics

PDF: 6